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Purpose: This study was undertaken to determine the neuro-
protective effect of granulocyte stimulating factor (G-CSF)
on neonatal hypoxic-ischemic brain injury. Materials and
Methods: Seven-day-old male newborn rat pups were
subjected to 110 minutes of 8% oxygen following a unilateral
carotid artery ligation. Apoptosis was identified by per-
forming terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) staining and flow cytometry
with a combination of fluorescinated annexin V and pro-
pidium iodide (PI) and JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolyl-carbocyanine iodide). The extent of
cerebral infarction was evaluated at 2 weeks after recovery.
Results: With a single dose (50 g/kg) of G-CSF treatment μ
immediately after hypoxic-ischemic insult, hypoxia-ischemia
induced increase in TUNEL-positive cells, annexinV+/PI-
and JC-1 positive apoptotic cells in the ipsilateral cerebral
cortex was significantly reduced at 24 hours, measured by
flow cytometry, and the extent of cerebral infarction at 2
weeks after recovery was also significantly attenuated com-
pared to the hypoxia-ischemia control group. Conclusion:
Our data suggest that G-CSF is neuroprotective by inhibiting
apoptosis, thereby reducing the ensuing cerebral infarction
in a newborn rat pup model of cerebral hypoxia-ischemia
(HI).
Key Words: Granulocyte stimulating factor, neuroprotective
agents, hypoxia-ischemia, newborn, apoptosis
INTRODUCTION
Despite uninterrupted improvements in fetal
monitoring and neonatal intensive care medicine,
perinatal hypoxic-ischemic encephalopathy still
remains an important cause of neonatal mortality
and permanent neurological sequelae such as
cerebral palsy, mental retardation, learning
disabilities, and epilepsy.
1 At present, there is no
clinically efficacious treatment available for this
common disorder. Therefore, the development of
a new therapeutic modality to improve the
prognosis of this disease is an urgent issue.
Recently, the neuroprotective effects of exoge-
nously administered G-CSF have been reported in
several adult animal models of ischemic brain
injury
2-8 as well as in phases I/II clinical studies
of stroke.
9,10 The neuroprotective effects exerted
by G-CSF are known to be mediated by a
multitude of mechanisms,
11 including inhibition of
apoptosis,
6 anti-inflammatory effects,
3 and
stimulation of endogenous stem cell prolifera-
tion.
7,8 G-CSF is one of the few growth factors that
have been approved for clinical use to treat
neutropenia, even in newborn infants.
12,13 Therefore,
any favorable experimental results can readily be
translated into clinical practice. However, results
obtained in adults cannot necessarily be
extrapolated into neonatal medicine due to the
dramatic differences in maturational stage and
pathophysiology of perinatal and adult brains. Up
to now, only 2 studies have reported the effects
of G-CSF in neonatal brain injury. While its
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beneficial effects have been shown in one study,
14
G-CSF was found to be detrimental to neonatal
brain injury in the other.
15 Therefore, the role of
G-CSF in neonatal brain injury is still contro-
versial, and further studies are necessary to clarify
this.
This study was undertaken to determine whether
G-CSF could reduce cerebral injury following HI
in the developing brain. As we have already
shown in our previous studies,
16,17 apoptosis plays
a major role in the development of hypoxic-
ischemic neonatal brain injury. In the present
study, we tested whether G-CSF is neuroprotective
by inhibiting apoptosis, thereby reducing the
ensuing cerebral infarction in a newborn rat pup
model of cerebral HI. Apoptosis was identified by
TUNEL staining and flow cytometry with a
combination of fluorescinated annexin V and
propidium iodide (PI) and JC-1 (5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzimidazolyl-carb
ocyanine iodide). The extent of cerebral infarction
was evaluated at 2 weeks after HI to determine
whether the neuroprotective effect, if any, of
G-CSF was transient or sustained.
MATERIALS AND METHODS
Hypoxia-ischemia
The experimental protocols described herein
were reviewed and approved by the Animal Care
and Use Committee of Samsung Biomedical
Research Center, Seoul, Korea. This study was
performed in accordance with the institutional
and National Institutes of Health guidelines for
laboratory animal care. Seven-day-old Sprague-
Dawley male rats (Daihan Biolink Co., Seoul,
Korea) weighing 13 - 16 g were used for the
experiments to exclude any gender-related
differences in brain injury.
18 The P7 male rat pups
(n = 56) were randomly divided into 3 groups: (1)
normoxia control group (NC, n = 18); (2) HI
control group (HC, n = 16); and (3) HI with G-CSF
treatment group (HG, n = 22). Cerebral HI was
induced by a modification of the method
16,17
originally reported by Rice et al.
19 The neck was
incised in the midline, and the right common
carotid artery was permanently ligated with 4 - 0
silk under methoxyflurane anesthesia. After 2
hours of recovery period, the animals were
exposed to 110 minutes of hypoxia (8% O2 /92%
N2) by placing them in airtight containers that
had been partially submerged in a 37°C water
bath to maintain a constant thermal environment.
Pups in NC received a Sham operation without
carotid artery ligation. Animals in HG received an
intraperitoneal injection of G-CSF (a kind gift
from Donga Pharm. Co., Seoul, Korea) at a dose
of 50 g/kg of body weight immediately after the μ
hypoxic insult,
8 or an equal volume of normal
saline as a NC and HC. Then, the pups were
returned to their dams and sacrificed at 24 hours
after HI for TUNEL stain and flow cytometry (n=
11 in NC, 7 in HC, and 11 in HG) under deep
pentobarbital anesthesia (60 mg/kg, intraperi-
toneal). The remaining rat pups (n = 7 in NC, 9 in
HC, and 11 in HG) were weighed daily for 2
weeks after HI until sacrifice for brain volume
measurements.
Preparation of brain specimens
Fresh whole brain tissue obtained at 24 hours
after HI was placed on a glass petri dish on ice
containing 1 - 2 mL of phosphate-buffered saline
(PBS), and transected in the coronal plane at the
level of the mid-dorsal hippocampus.
20 The
anterior portion of the right cerebral hemispheres
was processed for TUNEL staining, and the
posterior portion of the cerebral hemisphere
within the middle cerebral artery territory,
approximately 100 mg/block, was dissociated into
a single cell and used for flow cytometric
measurements.
16,17
TUNEL staining
The extent of DNA fragmentation was delineated
by analyzing brain tissue obtained from the
anterior half of the ipsilateral cerebral cortex using
a peroxidase in situ apoptosis detection kit S7100
(Chemicon International, Temecula, CA, USA) at
24 hours after HI. TUNEL-positive cells were
identified by an optical microscope with 400 high
power fields. Ten images were taken from each
sample and the number of TUNEL-positive cells
on a high power field was determined.Bong Rim Kim, et al.
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Flow cytometry
To evaluate the extent of apoptotic and necrotic
cells, the posterior portion of the ipsilateral
cerebral cortex was dissociated into a single cell
and flow cytometry was done with a combination
of PI (Sigma, St. Louis, MO, USA) and annexin
V-FITC (fluorescein isothiocyanate) (Pharmingen,
San Diego, CA, USA). Flow cytometric analysis
was performed by PAS (Particle Analyzing
System, Partec, Münster, Germany) equipped with
an argon ion laser tuned at 488 nm wavelength.
Green FITC-annexin V fluorescence was measured
at 530 ± 15 nm, and red PI fluorescence was
measured at 600 nm.
16,17
Mitochondrial membrane potential was
estimated using fluorescent probe JC-1 (Molecular
Probes, Eugene, OR, USA).
21 The dissociated
cortical cell suspensions were adjusted to the
density of 1 × 10
6 cells/mL and stained for 20
minutes with 2.0 g/mL of JC-1 at 37°C. JC-1 was μ
excited with the 488 nm argon laser, and JC-1
green and orange fluorescences were recorded on
FL1 (530 ± 15 nm band pass filter) and FL2 (575
± 13 nm band pass filter) channels.
Brain volume measurement
After transcardiac perfusion with 0.1 M of PBS,
the brains were carefully removed at 2 weeks after
HI and blocked with paraffin after overnight
fixation with 4% paraformaldehyde. The 5 m μ
thick serial sections were made at an interval of
100 m and stained with hematoxylin-eosin for μ
volumetric analysis.
All volumetric qualifications were performed
with an Olympus BX 40 photomicroscope (Olympus
Optical Co., Ltd., Tokyo, Japan) equipped with a
high resolution CCD camera, a motorized XYZ
axis computer-controlled stage, and Stereoinves-
tigator software package (ver. 6.52, Micro Bright
Field, VT, USA). When calculating volume, the
cross-sectional areas of the region of interest (ROI)
in each section were traced on the computer
screen at low power with a 1.5 ×/4 × lens, and
volume of the ROI was calculated by using the
Stereoinvestigator software according to Cavalieri's
principle.
22
Using this sampling strategy, approximately 8
histology sections per brain in the affected and
control hemisphere in each animal were evaluated
for hemispheric measurements. For anatomical
evaluation of the extent of cerebral injury, the
ratio of the ipsilateral remaining cerebral hemis-
phere volume to the volume of the corresponding
contralateral cerebral hemisphere is expressed as
a percentage. An examiner blind to the treatment
group quantified.
Statistical analysis
All data are expressed as mean ± standard
deviation. Kruskal-Wallis test was used for multiple
group comparisons followed by Wilcoxon rank
sum test including Bonferroni adjustment for a
comparison between 2 groups. All statistical
analyses described above were carried out using
the SAS Enterprise Guide version 3 (SAS Institute,
Cary, NC, USA). A p value of < 0.05 was con-
sidered significant.
RESULTS
TUNEL staining
In the ipsilateral anterior portion of the cerebral
cortex at 24 hours after HI significantly increased
numbers of TUNEL-positive cells were observed
in HC compared to NC (59.6 ± 9.2 vs. 0.2 ± 0.1, p
< 0.01). However, this increase in the number of
apoptotic cells was significantly attenuated in HG
compared to HC (14.3 ± 16.9 vs. 59.6 ± 9.2, p < 0.05)
(Fig. 1).
Flow cytometry
Representative analyses and regional percentage
of an annexin V versus PI dot plot of the
ipsilateral cerebral cortex in NC, HC, and HG at
24 hours after HI are presented in Fig. 2A. In HG,
the increased percentage of apoptotic cells in Q4
(annexin V+/PI-) and decreased percentage of live
cells in Q3 (annexin V-/PI-) observed in HC were
significantly improved but the attenuation of
secondary necrotic cells in Q2 (annexin V+/PI+)
did not reach statistical significance, and the
damaged cells in Q1 (annexin V-/PI+) were notG-CSF for Hypoxic-ischemic Neonatal Brain Injury
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significantly different from those in HC (Table 1).
Fig. 2B shows representative flow cytometric
analyses of mitochondrial membrane potential
using JC-1. In HG, increased cell percentage of
JC-1 fluorescence shifted from orange to green,
indicating a collapse of mitochondrial membrane
potential, was significantly attenuated compared
to HC (Table 1).
Body weight gain
Significantly retarded body weight gain was
observed in HC compared to NC, starting from 3
days after HI (p < 0.05). The weight gain, which is
indicative of general well being, was significantly
improved in HG from 10 days after HI compared
to HC (p < 0.05) (Fig. 3).
Measurement of brain volume
In HC, there was a significant decrease in per
centage of intact ipsilateral hemispheric volume
compared to NC (p < 0.01) at 2 weeks after HI
Fig. 1. Representative photomicrographs of TUNEL
staining (A) at the anterior portion of the ipsilateral
cerebral cortex (× 400) and number of TUNEL-positive
cells (B) per high power field in the NC, HC, and HG
groups at 24 hours after HI. Note significantly increased
TUNEL-positive green cells in HC compared to NC and
less TUNEL-positive cells in HG compared to HC. All
data are mean ± standard deviation. *p < 0.05 compared to
NC. p <0.05 compared to HC. NC, normoxia control group;
HC, HI control group; HG, HI with G-CSF treatment
group.
Fig. 2. (A) Representative flow cytogram of an annexin V binding (abscissa) versus PI uptake (ordinate) in the ipsilateral
cerebral hemisphere of newborn rat brain cells at 24 hours after HI. The numbers in the upper left quadrant (Q1), upper
right quadrant (Q2), lower left quadrant (Q3), and lower right quadrant (Q4) represent the percentage of damaged (annexin
V-/PI+), necrotic (annexin V+/PI+), live (annexin V-/PI-) and apoptotic cells (annexin V+/PI-), respectively. (B)
Representative flow cytometric analyses of mitochondrial membrane potential using JC-1. The shift of JC-1 fluorescence
from orange (FL2) to green (FL1) indicates a collapse of mitochondrial membrane potential. NC, normoxia control group;
HC, HI control group; HG, HI with G-CSF treatment group.
A
B
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injury. The HG group showed a marked pro-
tective effect and significantly increased percentage
of ipsilateral hemispheric volume compared to the
HC group (p < 0.01) 2 weeks after HI (Fig. 4).
DISCUSSION
In the present study, G-CSF significantly
attenuated the HI-induced loss of body weight
and increased apoptosis and ensuing cerebral
infarction in the newborn rat. In accordance with
our data, Yata et al.
14 have also reported the
neuroprotective effects of G-CSF in neonatal-
hypoxic ischemic brain injury. The safety and
feasibility of G-CSF have been demonstrated in
recent human stroke therapy trials.
9,10 Furthermore,
G-CSF is already available clinically in neonates.
12,13
Taken together, these findings strongly support
the potential use of G-CSF as therapeutic agents
in the clinical setting of perinatal hypoxic ischemic
encephalopathy where effective treatments have
not yet been established.
Although the mechanisms by which G-CSF
serves a neuroprotective agent have not fully been
clarified, G-CSF may act in a coordinated fashion
Table 1. Regional Cell Percentage of Ipsilateral Cerebral Hemisphere at 24 Hours after Hypoxia-ischemia
Q1 (%) Q2 (%) Q3 (%) Q4 (%) JC-1(%)
NC (n = 11) 0.26 ± 0.14 0.53 ± 0.26 85.96 ± 2.34 13.00 ± 2.20 0.25 ± 0.23
HC (n = 7) 1.80 ± 0.64* 9.41 ± 2.75* 62.01 ± 6.46* 26.39 ± 5.47* 31.50 ± 11.32*
HG (n = 11) 1.44 ± 1.56* 4.80 ± 4.72* 74.60 ± 0.88* 19.13 ± 5.00* 15.22 ± 19.74*
Q1, damaged (annexinV-/PI+) cells; Q2, necrotic (annexinV+/PI+) cells; Q3, live (annexinV-/PI-) cells; Q4, apoptotic
(annexinV+/PI-) cells; NC, normoxia control group; HC, HI control group; HG, HI with G-CSF treatment group.
All values given are mean ± standard deviation.
*p < 0.05 compared to NC.
p < 0.05 compared to HC.
Fig. 3. Body weight gain, indicative of general well being,
in the rat pups of each experimental group. Significantly
less body weight gain was observed in HC compared to
NC staring from 3 days after HI, and was improved in
HG from 10 days after HI compared to HC. NC, normoxia
control group; HC, HI control group; HG, HI with G-CSF
treatment group. All data are mean ± standard deviation.
*p < 0.05 compared to NC. p < 0.05 compared to HC.
Fig. 4. Representative photomicrographs of hematoxylin/
eosin staining (A) at the anterior commisure and per-
centage of the preserved brain volume (B) from the
normoxia control (NC), HI control (HC), and HI with
G-CSF treatment (HG) groups at 2 weeks after the injury.
Significantly increased infarct volume in HC compared to
NC, and significantly reduced infarct volume of HG com-
pared to HC are observed. NC, normoxia control group;
HC, HI control group; HG, HI with G-CSF treatment
group. All values are mean ± standard deviation. *p < 0.05
compared to NC. p < 0.05 compared to HC.
A
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at multiple levels,
11 including inhibition of
apoptosis,
6 modulation of inflammation,
3 and
recruitment of endogenous stem cells.
7,8 In the
present study, TUNEL staining was performed to
detect nuclear DNA breakdown, a common
feature of apoptosis.
23 Flow cytometry using
annexin V was done to detect exposure of phos-
phatidylserine outside of the plasma membrane,
the early and most characteristic change of
apoptosis.
24,25 PI was used to detect the disruption
of the plasma membrane and alterations in
permeability observed in necrotic cells. Decreased
mitochondrial membrane potential, observed
during early apoptosis, were measured by counting
the shift of JC-1 fluorescence from orange to green
with flow cytometry.
21 Together, our data on HI-
induced increase in TUNEL-positive cells, apoptotic
(annexin V+/PI-) cells, and JC-1 fluorescence shifted
from orange to green support the assumption that
apoptosis is the primary mode of cell death
following HI in the developing brain.
16,17,26 Our
data of significant attenuation of these abnor-
malities with G-CSF treatment also support the
assumption that the neuroprotective action of
G-CSF is mediated mainly by inhibition of
apoptosis in a newborn rat model of cerebral HI.
14
In the present study, a single dose of G-CSF
given immediately after HI significantly attenuated
the cerebral infarction at 2 weeks after HI. These
results implicate that the neuroprotective effects
of G-CSF are not transient. In our previous
studies,
16,17 we have shown that apoptosis plays
an important role in the development of delayed
infarction, and that the inhibition of apoptosis
with cycloheximide significantly attenuates
ensuing cerebral infarction in the newborn rat
model of cerebral HI. Therefore, our data on
significant reduction of infarction with G-CSF
treatment strongly suggest that G-CSF given
immediately after HI could attenuate and prevent
the activation of subsequent neurotoxic, probably
apoptotic cascade, ultimately leading to irreversible
neuronal cell death and delayed cerebral infarction
occurring days or months later.
26-29
In the present study, G-CSF was given imme-
diately after HI. However, as most asphyxial
events occur before birth and enrollment of
newborns for clinical trials can take at least
several hours for a mother to recover from a
delivery and to give informed consent, it is practi-
cally impossible to start any therapy immediately
after birth. There is a danger that delay in applying
potentially brain-saving treatments beyond the
therapeutic window might abolish or drastically
reduce its therapeutic effectiveness.
17,27-29 Therefore,
the long therapeutic window of G-CSF reported in
both preclinical
8 and clinical studies of adult
stroke
9,10 suggests therapeutic potential of this
agent in humans with perinatal hypoxic-ischemic
encephalopathy. Further studies on dosage,
therapeutic window, and safety in neonates are
necessary for the successful translation of the
benefits of G-CSF treatment observed in this
animal study into clinical trials.
In summary, G-CSF was demonstrated to have
neuroprotective effects by inhibiting apoptosis,
reducing the ensuing cerebral infarction in a
newborn rat pup model of cerebral HI. Our data
suggest that G-CSF is a potentially novel
therapeutic agent in perinatal hypoxic-ischemic
encephalopathy, and further clinical studies are
warranted.
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